What is the market valuation of neglected tropical diseases diagnosis?

The market valuation of the neglected tropical diseases diagnosis is USD 8.11 billion in 2027.

What is the forecasted size of the neglected tropical diseases diagnosis industry?

Neglected Tropical Diseases Diagnosis Market size was more than USD 7.5 billion in 2026 and is set to grow at a 9.6% CAGR between 2027 and 2036, attaining USD 18.76 billion by 2036.

How are global disease elimination initiatives shaping demand in the neglected tropical diseases diagnosis market?

WHO-led elimination programs and SDG-aligned initiatives are driving planned procurement of diagnostic tools for surveillance, treatment targeting, transmission monitoring, and reporting, creating more consistent demand across public health programs.

How is improving diagnostic accessibility influencing market adoption in the neglected tropical diseases diagnosis market?

Expanded laboratory infrastructure and point-of-care technologies enable earlier detection, shorter turnaround times, and broader community screening, while strengthening demand for both decentralized testing solutions and centralized confirmatory laboratory services.

Why do conventional diagnostic methods hold the largest share of the neglected tropical diseases diagnosis market?

Conventional methods held a 53.55% share in 2026 because they align with existing laboratory infrastructure, workforce expertise, and established testing workflows across diagnostic settings.

Which service type is growing fastest in the neglected tropical diseases diagnosis market?

POC services are the fastest-growing segment as healthcare providers seek faster testing, improved accessibility, and reduced logistical barriers in remote and resource-constrained environments.

Why does Asia Pacific lead the neglected tropical diseases diagnosis market?

Asia Pacific held a 33.46% share in 2026, driven by large affected populations and sustained demand for screening, testing, and surveillance.

How is North America expanding in neglected tropical diseases diagnosis?

North America is projected to grow at a 7.01% CAGR due to stronger diagnostic preparedness, advanced testing, and increased clinical awareness.

Which companies dominate the neglected tropical diseases diagnosis landscape?

Prominent companies in the neglected tropical diseases diagnosis market include F. Hoffmann-La Roche Ltd (Switzerland), Abbott Laboratories (United States), Thermo Fisher Scientific Inc. (United States), QIAGEN N.V. (Germany), Becton, Dickinson and Company (United States), bioMérieux SA (France), Sysmex Corporation (Japan), Seegene Inc. (South Korea), InBios International, Inc. (United States), Omega Diagnostics Group PLC (United Kingdom).